Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of OROS Methylphenidate vs Ritalin vs Placebo in Children with ADHD
NCT00269802Phase 3Completed
- Sponsor
- ALZA Corporation
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of methylphenidate osmotic release oral system in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by ALZA Corporation. Primary endpoint: IOWA Conners Rating Scale (Inattention/Overactivity subscale) rating by the teacher at Day 27. Status: completed.
02
Drugs
methylphenidate osmotic release oral system
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00269802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269802.